Bristol Pays Tranzyme $10 Million For Collaboration For Discovery Program
This article was originally published in The Pink Sheet Daily
Executive Summary
Tranzyme’s first alliance with a Big Pharma should give it a cushion to advance its own pipeline, which includes two Phase II candidates.